Form 4: Cadrenal CEO Quang Pham Sells Shares via 10b5-1 Plan

Cadrenal Therapeutics CEO and Chairman Quang Pham disclosed the sale of 12,763 shares of common stock executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• CEO and Chairman Quang Pham sold a total of 12,763 shares of Cadrenal Therapeutics (CVKD) common stock between May 11, 2026, and May 28, 2026.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025.
• The shares were sold at weighted average prices ranging from $4.93 to $5.76 per share.
• Following these transactions, the reporting person maintains direct ownership of 182,161 shares and indirect ownership of 200,000 shares through The PVBQ Living Trust.
• The filing includes a correction to a previous Form 4 filing regarding the number of shares indirectly owned.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while insider selling can be perceived negatively, the use of a pre-arranged 10b5-1 plan suggests these are routine liquidity events rather than reactive selling.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading by scheduling sales in advance.

Negatives

• The CEO and Chairman is reducing his direct equity stake in the company.
• The filing notes a previous administrative error in a May 26, 2026, filing that understated indirect share ownership.

Risks

• Continued selling by company insiders may signal a lack of confidence in near-term stock performance to retail investors.
• The company remains subject to the volatility inherent in the biotechnology sector.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of insider transaction activity.

Management Comments

• The reporting person confirms that the sales were made in accordance with a Rule 10b5-1 trading arrangement.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives to diversify holdings and is generally viewed as neutral by the market, provided the sales are consistent with the established plan.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate executives to manage equity holdings while maintaining compliance with SEC regulations.
• The disclosure of weighted average prices and the commitment to provide full transaction details upon request aligns with standard SEC reporting transparency requirements.

Corporate Governance

Related Party Transactions

• The reporting person is the Trustee of The PVBQ Living Trust, which holds 200,000 shares of the issuer.

Stakeholder Impact

• Shareholders should note the reduction in the CEO's direct equity position, though the impact is mitigated by the use of a pre-planned trading arrangement.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Cadrenal Therapeutics, CVKD, Insider Trading, Quang Pham, Form 4, Biotech, Rule 10b5-1